Facebook Instagram X-twitter Linkedin Youtube Spotify Apple

Clinical Trials

For a quick look at enrolling or soon to be enrolling investigational drug studies in Duchenne and their enrollment criteria, check out our Clinical Trial Cheat Sheet below.
Clinical Trial Cheat Sheet

Clinical Trial Finder

Use this Clinical Trial Finder below that can help provide you with more information regarding clinical trials in Duchenne that that you, your child, or your patient may be eligible for!

Watch Jett Foundation's Mini Satellite Presentation

Emerging Therapies for Duchenne Muscular Dystrophy

Presented by Jean Mah, M.D., Associate Professor of Pediatric Neurology Alberta Children’s Hospital at the 2016 Child Neurology Society Meeting to learn more about these potential therapies!

Latest Duchenne News

March 12, 2026

Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial

On March 11, 2026, Solid Biosciences Inc. reported updated positive interim data from the ongoing Phase 1/2 INSPIRE DUCHENNE clinical trial of SGT-003. They shared these updates in both a...
Read More
March 11, 2026

REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202

On March 11, 2026, REGENXBIO Inc. announced new positive interim data from the Phase I/II AFFINITY DUCHENNE trial of RGX-202, a potential best-in-class gene therapy for Duchenne muscular dystrophy. They...
Read More
March 11, 2026

ITF Therapeutics: New data and analyses presented on DUVYZAT® (givinostat) at 2026 MDA Clinical and Scientific Conference

On March 11, 2026, ITF Therapeutics shared a Community Letter outlining new data and analyses presented on DUVYZAT® (givinostat) at 2026 MDA Clinical and Scientific Conference. To view their Community...
Read More
March 11, 2026

Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up

On March 10, 2026, Edgewise Therapeutics, Inc. presented at the 2026 MDA Clinical and Scientific Conference, long-term data from its MESA open-label extension study of sevasemten in Becker muscular dystrophy...
Read More
March 9, 2026

Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)

On March 8, 2026, Dyne Therapeutics, Inc. (Nasdaq: DYN) announced additional positive data from the ongoing Phase 1/2 DELIVER clinical trial of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251), in...
Read More
February 26, 2026

Entrada Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

On February 26, 2026, Entrada Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2025, and highlighted recent business updates. This full release can...
Read More
Register Now

Experience the magic this summer!

Apply Today

How is the rare disease community accomplishing goals?

Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!

Register Today

Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.

Give Today

Accessible Vehicle Fund Applications Open

Apply Today